HRMY Stock Risk & Deep Value Analysis
Harmony Biosciences Holdings Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About HRMY Stock
We analyzed Harmony Biosciences Holdings Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran HRMY through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Moderate. Here's what we found.
HRMY Risk Analysis & Red Flags
What Could Go Wrong
Harmony Biosciences' revenue is heavily concentrated on WAKIX. A significant competitive threat, an unexpected adverse event, or a patent challenge that erodes its intellectual property protection could severely impact its primary revenue stream, currently annualized at approximately $860M based on Q1 2026 results. Without robust pipeline diversification, this single-asset reliance prevents achieving 10x growth potential.
Risk Matrix
Overall
Moderate
Financial
Low
Market
Medium
Competitive
Medium
Execution
Medium
Regulatory
Medium
Red Flags
- ⚠
Affiliate insider selling: Sandip Kapadia sold shares totaling over $1.7 million in May-June 2026, including 45,481 shares on 05/08/2026.
- ⚠
Past EPS misses: As per previous analysis, Q4 2025 and Q1 2026 EPS misses despite revenue growth raise questions about earnings quality.
- ⚠
Concentration risk: Revenue almost entirely dependent on WAKIX, making the company vulnerable to market shifts or competitive pressures in its specific indications.
Upcoming Risk Events
- 📅
Q2 2026 earnings miss (estimated early-August 2026): Failure to meet consensus EPS and/or revenue expectations, signaling continued execution issues.
- 📅
Negative results from an ongoing clinical trial for a pipeline candidate or new WAKIX indication (e.g., Phase 3 for pediatric narcolepsy), potentially delaying future revenue diversification.
When to Reconsider
- 🚪
Exit if quarterly WAKIX net product revenue growth falls below 10% year-over-year for two consecutive quarters.
- 🚪
Sell if net income turns negative for two consecutive quarters, indicating a fundamental shift in profitability trajectory.
- 🚪
Exit if a major patent for WAKIX is successfully challenged or invalidated, significantly impacting revenue protection beyond the 2030s.
Unlock HRMY Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Harmony Biosciences Holdings Inc (HRMY) Do?
Market Cap
$1.99B
Sector
Healthcare
Industry
Biotechnology
Employees
268
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 1 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and High-Dose (HD). In addition, the company's products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome (FXS), rare genetic disorder that causes inherited intellectual disability and autism spectrum disorder; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome. Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; and EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies (DEE). The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
Visit Harmony Biosciences Holdings Inc WebsiteInvestment Thesis
If Harmony Biosciences successfully expands the WAKIX franchise through new indications (e.g., pediatric narcolepsy, idiopathic hypersomnia), adding at least $300M in annual revenue by 2028, and/or acquires a complementary neurology asset with >$500M peak sales potential that achieves similar market penetration to WAKIX by 2030, then its annual revenue could surpass $1.5B against a current ~$860M annualized, potentially leading to a market re-rating to 4-5x P/S from current ~2.3x P/S, pushing valuation towards $4-5B (2-3x from current $1.99B) before factoring in further pipeline success.
Is HRMY Stock Undervalued?
Unlock the full AI analysis for HRMY
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
HRMY Price Targets & Strategy
12-Month Target
$50.00
Bull Case
$62.00
Bear Case
$28.00
Valuation Basis
Based on 15.6x forward P/E applied to estimated FY2026 EPS of $3.20.
Entry Strategy
Consider dollar-cost averaging between current price of $34.46 and a support zone around $30.00-$32.00.
Exit Strategy
Take profit on 50% of position at $50.00, with a stop loss below $28.00 (lowest analyst target).
Portfolio Allocation
5% for moderate risk tolerance
Price Targets & Strategy
Sign up free to unlock price targets and entry/exit strategies
Is HRMY Financially Healthy?
Valuation
P/E Ratio
13.70
Forward P/E
13.70
EV/EBITDA
21.50
PEG Ratio
1.20
Price/Book
4.60
Price/Sales
2.60
Profitability
Gross Margin
76.55%
Operating Margin
21.08%
Net Margin
16.20%
Return on Equity
17.19%
Revenue Growth
20.71%
EPS
$2.49
Balance Sheet
Current Ratio
3.60
Quick Ratio
3.51
Debt/Equity
0.19
Total Debt
$92.00M
Cash & Equivalents
$541.00M
Cash Flow
Operating Cash Flow
$141.00M
Free Cash Flow
$112.00M
EBITDA
$189.00M
Other
Beta (Volatility)
0.96
Does HRMY Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Stable
Moat Sources
1 Identified
The moat is primarily derived from WAKIX's patent protection, which extends through the 2030s. This provides a clear, albeit time-limited, period of exclusivity. Its durability beyond this timeframe heavily depends on successful pipeline expansion and new intellectual property development.
Moat Erosion Risks
- •Patent invalidation challenges or the entry of new, highly effective competitive therapies for narcolepsy.
- •Failure to diversify the product pipeline, making the company overly reliant on a single asset once WAKIX's patent exclusivity expires.
HRMY Competitive Moat Analysis
Sign up to see competitive advantages
HRMY Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral - No specific strong positive or negative sentiment signals are available in the provided research, suggesting general market indifference or moderate discussion.
Institutional Sentiment
Neutral - Analyst consensus is 'Hold' with an average price target of $40.89, indicating moderate upside potential but no strong institutional conviction for significant outperformance.
Insider Activity (Form 4)
CFO Glenn Reicin received a stock option grant (routine compensation) on 05/06/2026. Sandip Kapadia (affiliate) sold 2,101 shares ($69,504.02) on 06/05/2026, 7,064 shares ($233,232.09) on 06/04/2026, and 45,481 shares ($1,433,056.28) on 05/08/2026.
Options Flow
Normal options activity - No unusual put/call ratio or large block trades indicative of strong institutional positioning mentioned in the provided research.
Earnings Intelligence
Next Earnings
Estimated early-August 2026 (for Q2 2026 results)
Surprise Probability
Medium
Historical Earnings Pattern
Previous analysis noted EPS misses in Q4 2025 and Q1 2026 raised concerns about short-term profitability, suggesting potential negative market reaction to future misses, despite revenue growth.
Key Metrics to Watch
Competitive Position
Top Competitor
Jazz Pharmaceuticals ($JAZZ)
Market Share Trend
Stable/Gaining (for WAKIX within its specific narcolepsy indications)
Valuation vs Peers
Harmony Biosciences typically trades at a comparable P/E to specialty pharma peers but may be at a slight discount on an EV/Sales basis due to its smaller market cap and reliance on a single primary drug.
Competitive Advantages
- •Patented drug (pitolisant/WAKIX) with intellectual property protection through the 2030s.
- •Established commercial infrastructure and expertise in rare neurological diseases.
- •Strong market penetration in its approved indications for narcolepsy.
Market Intelligence
Sign up free to unlock sentiment, earnings intel, and peer analysis
What Could Drive HRMY Stock Higher?
Near-Term (0-6 months)
- •Q2 2026 earnings release (estimated early-August 2026): Positive EPS surprise with strong WAKIX revenue growth and an improved full-year guidance for 2026.
- •Update on Phase 3 trial for a new WAKIX indication (e.g., pediatric narcolepsy or idiopathic hypersomnia) with positive preliminary data (est. Q3 2026).
Medium-Term (6-18 months)
- •Announcement of a strategic acquisition of a complementary neurology asset with a market opportunity of >$500M annual peak sales (6-12 months).
- •Submission of a New Drug Application (NDA) or Supplemental NDA (sNDA) for a significant new indication for WAKIX or a novel pipeline candidate, backed by positive Phase 3 results (12-18 months).
Long-Term (18+ months)
- •FDA approval and successful commercial launch of a new product or WAKIX indication, achieving >$200M in annual incremental revenue by 2029.
- •Sustained intellectual property protection for WAKIX through 2030s, securing current revenue base and enabling further market expansion (beyond 18 months).
Catalysts & Growth Drivers
Sign up free to see growth catalysts
What's the Bull Case for HRMY?
- ✓
Watch for FDA approval of new WAKIX indications (e.g., for pediatric narcolepsy) with specified launch timelines and revenue projections.
- ✓
Track total value and strategic fit of M&A deals to diversify pipeline; a significant acquisition (> $500M) could be a strong signal for future growth.
Bull Case Analysis
Sign up free to see the bull case
Competing with HRMY
See how Harmony Biosciences Holdings Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Harmony Biosciences Holdings Inc HRMY | $2.0B | 7.5 | 13.7 | $520.0M | 16.2% | 20.7% | |
AbbVie Inc ABBV | $381.1B | 0.1 | 104.8 | $15.0B | 5.8% | 9.5% | Compare → |
Johnson & Johnson JNJ | $557.1B | 1.0 | 26.5 | — | 21.8% | 7.9% | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $146.4B | 4.0 | 19.5 | $62.6B | 11.8% | 1.4% | Compare → |
UnitedHealth Group Inc UNH | $365.5B | 0.3 | 30.3 | $447.6B | 2.7% | 9.7% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Harmony Biosciences Holdings Inc Makes Money
Harmony Biosciences is a commercial-stage biopharmaceutical company that develops and sells therapies for rare and other neurological diseases. Its primary product is WAKIX (pitolisant), a patented drug approved for treating excessive daytime sleepiness or cataplexy in adult patients with narcolepsy. The company generates revenue by manufacturing, marketing, and selling WAKIX to patients through healthcare providers and pharmacies. This model leverages the high-margin nature of patented specialty pharmaceuticals, supported by a focused sales force and ongoing research into new indications.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Harmony Biosciences Holdings Inc (HRMY)?
As of June 15, 2026, Harmony Biosciences Holdings Inc has a DVR Score of 7.5 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Harmony Biosciences Holdings Inc?
Harmony Biosciences Holdings Inc's market capitalization is approximately $2.0B. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Harmony Biosciences Holdings Inc use?
HRMY is the ticker symbol for Harmony Biosciences Holdings Inc. The company trades on the NGM.
What is the risk level for HRMY stock?
Our analysis rates Harmony Biosciences Holdings Inc's overall risk as Moderate. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of HRMY?
Harmony Biosciences Holdings Inc currently has a price-to-earnings (P/E) ratio of 13.7. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Harmony Biosciences Holdings Inc's revenue growing?
Harmony Biosciences Holdings Inc has reported revenue growth of 20.7%. The company is showing strong top-line momentum.
Is HRMY stock profitable?
Harmony Biosciences Holdings Inc has a profit margin of 16.2%. The company is profitable but margins are modest.
How often is the HRMY DVR analysis updated?
Our AI-powered analysis of Harmony Biosciences Holdings Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on June 15, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for HRMY (Harmony Biosciences Holdings Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.